Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime BA Story by MedicilonOn July 14, the IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license and agreed to carry out phase I clinOn July 14, the IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license and agreed to carry out phase I clinical trials. The indication is ulcerative colitis. Shanghai Medicilon Inc, as a strategic partner of Biotime Biotechnology, provided preclinical R&D services from target to IND declaration for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency. BIOT-001 is an innovative small-molecule drug independently developed by Biotime Biotechnology with global intellectual property rights. BIOT-001 is an orally active receptor agonist targeting S1P1. Preclinical studies have shown that BIOT-001 can selectively bind to S1P receptor subtype 1 (S1P1) with high affinity, thereby inducing the isolation of peripheral blood lymphocytes, reducing the migration of activated circulating lymphocytes to the gastrointestinal tract, and has the effect of treating inflammatory bowel disease. At the same time, preclinical toxicology studies have shown that the drug has the characterize of good safety. About Biotime Biotechnology About Medicilon © 2023 Medicilon |
AuthorMedicilonCambridge, MAAboutMedicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services for pharmaceutical enterprises and scientific research institutions around the w.. more..Writing
|